TY - JOUR
T1 - Is CD20 positive plasma cell myeloma a unique clinicopathological entity? A study of 40 cases and review of the literature
AU - Grigoriadis, George
AU - Gilbertson, Michael
AU - Came, Neil
AU - Westerman, David A
AU - Fellepa, Frank
AU - Jene, Nick
AU - Chapple, Peter
AU - Juneja, Surender
PY - 2012
Y1 - 2012
N2 - Aims: A number of clinicopathological features have been attributed to the CD20 positive subset of plasma cell myeloma (PCM). CD20 is an appealing therapeutic target given the success with monoclonal antibody regimens in a spectrum of B cell lymphomas. To date, a small number of reports have described CD20+ PCM as a unique subset, and these are not conclusive, especially taking into consideration reporting bias. This study aims to further identify the clinicopathological features of CD20 + PCM. Methods: A retrospective analysis of all newly diagnosed PCM between 2003 and 2010 was undertaken. Trephine material was retrieved and reviewed for CD20, and for positive cases an extended immunohistochemical (IHC) panel including cyclin D1 was subsequently performed. Results: The review of our 40 cases and those described in the literature demonstrated that these are heterogeneous with regard to clinical features, morphology, biochemical features, immunophenotype, and cytogenetics. Conclusion: Based on our study and review of the literature, CD20 + PCM cases represent a heterogeneous disease and not a unique clinicopathological entity. ? 2012 Royal College of Pathologists of Australasia.
AB - Aims: A number of clinicopathological features have been attributed to the CD20 positive subset of plasma cell myeloma (PCM). CD20 is an appealing therapeutic target given the success with monoclonal antibody regimens in a spectrum of B cell lymphomas. To date, a small number of reports have described CD20+ PCM as a unique subset, and these are not conclusive, especially taking into consideration reporting bias. This study aims to further identify the clinicopathological features of CD20 + PCM. Methods: A retrospective analysis of all newly diagnosed PCM between 2003 and 2010 was undertaken. Trephine material was retrieved and reviewed for CD20, and for positive cases an extended immunohistochemical (IHC) panel including cyclin D1 was subsequently performed. Results: The review of our 40 cases and those described in the literature demonstrated that these are heterogeneous with regard to clinical features, morphology, biochemical features, immunophenotype, and cytogenetics. Conclusion: Based on our study and review of the literature, CD20 + PCM cases represent a heterogeneous disease and not a unique clinicopathological entity. ? 2012 Royal College of Pathologists of Australasia.
UR - http://www.ncbi.nlm.nih.gov/pubmed/22935987
U2 - 10.1097/PAT.0b013e3283583f5d
DO - 10.1097/PAT.0b013e3283583f5d
M3 - Article
SN - 0031-3025
VL - 44
SP - 552
EP - 556
JO - Pathology
JF - Pathology
IS - 6
ER -